SIM
PRQR icon

Spark Investment Management’s ProQR Therapeutics PRQR Stock Holding History

Spark Investment Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-21,900
Closed -$190K – 816
2015
Q4 		$190K Buy
+21,900
New +$252K 0.02% 588

Other funds holding PRQR

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Spark Investment Management's PRQR Position: Q1 2016 in Review

Spark Investment Management sold out of ProQR Therapeutics (PRQR) in Q1 2016, closing a stake of 21,900 shares — an estimated $190K sold.

Spark Investment Management first reported a position in PRQR in Q4 2015 and held it in 1 quarter. The position peaked at $190K in Q4 2015. 29 funds tracked by Wall St. Rank hold PRQR as of Q1 2016.

  • Spark Investment Management reported no remaining ProQR Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Spark Investment Management sold 21,900 ProQR Therapeutics shares in Q1 2016, an estimated $190K.
  • Spark Investment Management first reported a position in ProQR Therapeutics in Q4 2015 and held it in 1 quarter.
  • Spark Investment Management's ProQR Therapeutics position peaked at $190K in Q4 2015.
  • 29 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2016.

Based on Spark Investment Management's 13F filing for Q1 2016, filed 12 May 2016.